3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
2
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
26
Lymphoma, Large B-Cell, Diffuse
19
Burkitt Lymphoma
13
Precursor Cell Lymphoblastic Leukemia-Lymphoma
9
Lymphoma, T-Cell, Peripheral
8
Lymphoma, Follicular
8
Lymphoma, B-Cell
7
Lymphoma
7
Neoplasms
5
Lymphoma, Non-Hodgkin
5
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3
Neoplasm Metastasis
3
Leukemia, Biphenotypic, Acute
3
Recurrence
2
Prostatic Neoplasms, Castration-Resistant
2
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
2
Plasmablastic Lymphoma
2
Ovarian Neoplasms
2
Myasthenia Gravis
2
Lymphoma, Mantle-Cell
2
Lymphoma, B-Cell, Marginal Zone
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Endometrial Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Urogenital Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Prostatic Diseases
1
Prostate Cancer Metastatic
1
Prostate Adenocarcinoma
1
Interventions
enzalutamide
4
Docetaxel
2
pembrolizumab
1
olaparib
1
lenvatinib
1
inavolisib
1
belzutifan
1
abiraterone
1
Prednisone
1
PF06821497
1
Lutetium-177
1
Lutetium
1
Gonadotropin-Releasing Hormone
1
Etoposide
1
Dexamethasone
1
Carboplatin
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Metastatic Castration-Resistant Prostate Cancer
×
Prednisone
×
Clear all
NCT02861573
2026-02-17
KEYNOTE-365
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
1,200 enrolled